Deficits in striatal dopamine release in cannabis dependence

Most drugs of abuse lead to a general blunting of dopamine release in the chronic phase of dependence, which contributes to poor outcome. To test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabi...

Full description

Bibliographic Details
Main Authors:	van de Giessen, Elsmarieke, Weinstein, Jodi J., Cassidy, Clifford M., Haney, Margaret, Dong, Zhengchao, Ghazzaoui, Rassil, Ojeil, Najate, Kegeles, Lawrence S., Xu, Xiaoyan, Vadhan, Nehal P., Volkow, Nora D., Slifstein, Mark, Abi-Dargham, Anissa
Format:	Online
Language:	English
Published:	2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033654/

id	pubmed-5033654
recordtype	oai_dc
spelling	pubmed-50336542016-12-21 Deficits in striatal dopamine release in cannabis dependence van de Giessen, Elsmarieke Weinstein, Jodi J. Cassidy, Clifford M. Haney, Margaret Dong, Zhengchao Ghazzaoui, Rassil Ojeil, Najate Kegeles, Lawrence S. Xu, Xiaoyan Vadhan, Nehal P. Volkow, Nora D. Slifstein, Mark Abi-Dargham, Anissa Article Most drugs of abuse lead to a general blunting of dopamine release in the chronic phase of dependence, which contributes to poor outcome. To test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabis dependent participants (CD), free of any comorbid conditions, including nicotine use. Eleven CD and twelve healthy controls (HC) completed two positron emission tomography scans with [11C]-(+)-PHNO, before and after oral administration of d-amphetamine. CD stayed inpatient for 5–7 days prior to the scans to standardize abstinence. Magnetic Resonance Imaging (MRS) measures of glutamate in the striatum and hippocampus were obtained in the same subjects. Percent change in [11C]-(+)-PHNO binding potential (ΔBPND) was compared between groups and correlations with MRS glutamate, subclinical psychopathological and neurocognitive parameters were examined. CD had significantly lower ΔBPND in the striatum (p=0.002, effect size (ES)=1.48), including the associative striatum (p=0.003, ES=1.39), sensorimotor striatum (p=0.003, ES=1.41), and the pallidus (p=0.012, ES=1.16). Lower dopamine release in the associative striatum correlated with inattention and negative symptoms in CD, and with poorer working memory and probabilistic category learning performance in both CD and HC. No relationships to MRS glutamate and amphetamine-induced subclinical positive symptoms were detected. In conclusion, this study provides evidence that severe cannabis dependence -without the confounds of any comorbidity- is associated with a deficit in striatal dopamine release. This deficit extends to other extrastriatal areas and predicts subclinical psychopathology. 2016-03-22 2017-01 /pmc/articles/PMC5033654/ /pubmed/27001613 http://dx.doi.org/10.1038/mp.2016.21 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	van de Giessen, Elsmarieke Weinstein, Jodi J. Cassidy, Clifford M. Haney, Margaret Dong, Zhengchao Ghazzaoui, Rassil Ojeil, Najate Kegeles, Lawrence S. Xu, Xiaoyan Vadhan, Nehal P. Volkow, Nora D. Slifstein, Mark Abi-Dargham, Anissa
spellingShingle	van de Giessen, Elsmarieke Weinstein, Jodi J. Cassidy, Clifford M. Haney, Margaret Dong, Zhengchao Ghazzaoui, Rassil Ojeil, Najate Kegeles, Lawrence S. Xu, Xiaoyan Vadhan, Nehal P. Volkow, Nora D. Slifstein, Mark Abi-Dargham, Anissa Deficits in striatal dopamine release in cannabis dependence
author_facet	van de Giessen, Elsmarieke Weinstein, Jodi J. Cassidy, Clifford M. Haney, Margaret Dong, Zhengchao Ghazzaoui, Rassil Ojeil, Najate Kegeles, Lawrence S. Xu, Xiaoyan Vadhan, Nehal P. Volkow, Nora D. Slifstein, Mark Abi-Dargham, Anissa
author_sort	van de Giessen, Elsmarieke
title	Deficits in striatal dopamine release in cannabis dependence
title_short	Deficits in striatal dopamine release in cannabis dependence
title_full	Deficits in striatal dopamine release in cannabis dependence
title_fullStr	Deficits in striatal dopamine release in cannabis dependence
title_full_unstemmed	Deficits in striatal dopamine release in cannabis dependence
title_sort	deficits in striatal dopamine release in cannabis dependence
description	Most drugs of abuse lead to a general blunting of dopamine release in the chronic phase of dependence, which contributes to poor outcome. To test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabis dependent participants (CD), free of any comorbid conditions, including nicotine use. Eleven CD and twelve healthy controls (HC) completed two positron emission tomography scans with [11C]-(+)-PHNO, before and after oral administration of d-amphetamine. CD stayed inpatient for 5–7 days prior to the scans to standardize abstinence. Magnetic Resonance Imaging (MRS) measures of glutamate in the striatum and hippocampus were obtained in the same subjects. Percent change in [11C]-(+)-PHNO binding potential (ΔBPND) was compared between groups and correlations with MRS glutamate, subclinical psychopathological and neurocognitive parameters were examined. CD had significantly lower ΔBPND in the striatum (p=0.002, effect size (ES)=1.48), including the associative striatum (p=0.003, ES=1.39), sensorimotor striatum (p=0.003, ES=1.41), and the pallidus (p=0.012, ES=1.16). Lower dopamine release in the associative striatum correlated with inattention and negative symptoms in CD, and with poorer working memory and probabilistic category learning performance in both CD and HC. No relationships to MRS glutamate and amphetamine-induced subclinical positive symptoms were detected. In conclusion, this study provides evidence that severe cannabis dependence -without the confounds of any comorbidity- is associated with a deficit in striatal dopamine release. This deficit extends to other extrastriatal areas and predicts subclinical psychopathology.
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033654/
_version_	1613659009176305664

Deficits in striatal dopamine release in cannabis dependence

Similar Items